Hamed Zare, Tahereh Farkhondeh, Hamid Bakherad, Hengame Sharifi, Maryam Hosseinzade Shirzeyli, Saeed Samarghandian and Fahimeh Ghasemi* Pages 428 - 434 ( 7 )
The coronavirus disease 2019 (Covid-19) pandemic has been considered a major threat to human health. Effective therapeutic approaches are urgently required. Spike protein and the Angiotensin-converting enzyme 2 (ACE2) receptors have critical roles in SARS-CoV-2 infection. As a result, these two proteins are considered potential targets for the development of a wide variety of biotherapeutics and vaccines for controlling Covid-19. The fusion proteins have desirable medicinal properties, including high serum half-life, stability, and solubility in the body. Moreover, other Fc-fusion proteins used to treat other diseases have no known side effects. These Fc-fusion proteins are valuable biopharmaceuticals and have been proposed as therapeutic candidates for the treatment and prevention of Covid-19 owing to their potential therapeutic benefits.
Fc-fusion proteins, Covid-19, SARS-CoV-2, Spike protein, ACE2, receptor.